Increasing constitutional challenges to FTC adjudication could hasten Supreme Court review
Following Amgen and Horizon Therapeutics’ recent counterclaim against the Federal Trade Commission alleging that the agency’s in-house court violates the Constitution, a blueprint has emerged for dealmakers to challenge the constitutionality...To view the full article, register now.
Already a subscriber? Click here to view full article